PMID- 37046637
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230415
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 7
DP  - 2023 Mar 26
TI  - The Role of cMET in Gastric Cancer-A Review of the Literature.
LID - 10.3390/cancers15071976 [doi]
LID - 1976
AB  - Gastric cancer (GC) is an important cause of cancer worldwide with over one 
      million new cases yearly. The vast majority of cases present in stage IV disease, 
      and it still bears a poor prognosis. However, since 2010, progress has been made 
      with the introduction of targeted therapies against HER2 and with checkpoint 
      inhibitors (PDL1). More agents interfering with other targets (FGFR2B, CLDN18.2) 
      are being investigated. cMET is a less frequent molecular target that has been 
      studied for gastric cancer. It is a proto-oncogene that leads to activation of 
      the MAPK pathway and the PI3K pathway, which is responsible for activating the 
      MTOR pathway. The prevalence of cMET is strongly debated as different techniques 
      are being used to detect MET-driven tumors. Because of the difference in 
      diagnostic assays, selecting patients who benefit from cMET inhibitors is 
      difficult. In this review, we discuss the pathway of cMET, its clinical 
      significance and the different diagnostic assays that are currently used, such as 
      immunohistochemy (IHC), fluorescence in situ hybridization (FISH), the H-score 
      and next-generation sequencing (NGS). Next, we discuss all the current data on 
      cMET inhibitors in gastric cancer. Since the data on cMET inhibitors are very 
      heterogenous, it is difficult to provide a general consensus on the outcome, as 
      inclusion criteria differ between trials. Diagnosing cMET-driven gastric tumors 
      is difficult, and potentially the only accurate determination of cMET 
      overexpression/amplification may be next-generation sequencing (NGS).
FAU - Van Herpe, Filip
AU  - Van Herpe F
AD  - Department of Digestive Oncology, University Hospitals Gasthuisberg, 3000 Leuven, 
      Belgium.
FAU - Van Cutsem, Eric
AU  - Van Cutsem E
AD  - Department of Digestive Oncology, University Hospitals Gasthuisberg, 3000 Leuven, 
      Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230326
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10093530
OTO - NOTNLM
OT  - cMET
OT  - gastric cancer
OT  - gastro-oesophageal cancer
OT  - review
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/14 06:00
MHDA- 2023/04/14 06:01
PMCR- 2023/03/26
CRDT- 2023/04/13 01:07
PHST- 2022/11/22 00:00 [received]
PHST- 2023/03/10 00:00 [revised]
PHST- 2023/03/23 00:00 [accepted]
PHST- 2023/04/14 06:01 [medline]
PHST- 2023/04/13 01:07 [entrez]
PHST- 2023/04/14 06:00 [pubmed]
PHST- 2023/03/26 00:00 [pmc-release]
AID - cancers15071976 [pii]
AID - cancers-15-01976 [pii]
AID - 10.3390/cancers15071976 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Mar 26;15(7):1976. doi: 10.3390/cancers15071976.